MediciNova, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
MNOV Nasdaq 8731 http://www.medicinova.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MediciNova, Inc.

Benzinga Pro's 5 Stocks To Watch Today - Apr 13th, 2018 6:30 am
MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France - Apr 13th, 2018 4:30 am
Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences — Renewed Outlook, Key Drivers of Growth - Apr 12th, 2018 6:20 am
The Week Ahead In Biotech: PDUFA Dates, IPOs And More - Apr 6th, 2018 10:55 am
Wired News – MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence - Apr 3rd, 2018 5:20 am
Why Limelight Networks, MediciNova, and Commvault Systems Jumped Today - Apr 2nd, 2018 2:30 pm
Here's Why MediciNova Jumped as Much as 26.2% Today - Apr 2nd, 2018 12:53 pm
MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis - Apr 1st, 2018 5:00 pm
MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence - Mar 29th, 2018 4:30 am
MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy - Mar 28th, 2018 5:00 pm
Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and MediciNova — New Horizons, Emerging Trends, and Upcoming Developments - Mar 15th, 2018 6:15 am
MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo - Mar 12th, 2018 5:00 pm
Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet? - Feb 21st, 2018 4:18 pm
MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California - Feb 18th, 2018 4:00 pm
MNOV: Raises $40 Million in Underwritten Public Offering - Feb 16th, 2018 8:30 am
MediciNova Announces Closing of Underwritten Public Offering of Common Stock - Feb 12th, 2018 4:30 pm
Here's Why MediciNova, Inc. Stock Is Sliding Today - Feb 8th, 2018 11:17 am
MediciNova Announces Pricing of Underwritten Public Offering of Common Stock - Feb 7th, 2018 5:12 pm
MediciNova Announces Proposed Underwritten Public Offering of Common Stock - Feb 7th, 2018 2:01 pm